In The Field - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

In The Field
Pharmaceutical Science & Technology News

Pharmaceutical Technology

Fifteen of twenty-two HINJ companies responded to the survey, which targeted functional area, occupational title, educational level, and degree, while data were collected on numbers of employees, job openings, recent hires, and employment projections. Structured interviews were conducted with human resources managers as well. The full report may be found at
-Angie Drakulich

FDA Issues Draft Guidance for Labeling Prescription Drugs
Rockville, MD (May)The US Food and Drug Administration (FDA) issued a draft guidance "Labeling for Human Prescription Drugs—Determining Established Pharmacologic Class for Use in the Highlights of Prescribing Information."

The guidance is meant to help applicants and review staff in FDA's Center for Drug Evaluation and Research "determine when a drug belongs to an established pharmacologic class" and "how to select the appropriate word or phrase that describes the pharmacologic class for inclusion in the Indications and Usage section of Highlights of Prescribing Information of approved labeling."

According to a final rule published by FDA in January 2006, a drug that is a member of an established pharmacologic class must have the name of the class and the drug's indications clearly labeled under the Indications and Usage section of Highlights. Pharmacologic class is defined on the basis of the drug's mechanism of action (MOA), physiologic effect (PE), or chemical structure (CS).

According to the new draft, a single drug can have multiple scientifically valid pharmacologic classes. Only the pharmacologic classes that are clinically meaningful (that is, they enhance the ability of professionals to understand the therapeutic effects or undesirable effects of the drug) as well as scientifically valid can be the drug's established pharmacologic class. The draft goes on to give several examples of how to determine the correct pharmacologic class for a drug and the circumstances in which a combination of established pharmacologic classes may be included on the drug's label.

FDA goes on to state that new drugs undergoing review for marketing or licensing approval will have their proposed established pharmacologic class reviewed by FDA for scientific validity based on submitted evidence that supports the claim that the pharmacologic class is known and relevant to the indication under review. If an applicant wishes to update the labeling for an approved drug, the addition of an established pharmacologic class term to the Indications and Usage section must be proposed and submitted in a prior-approval labeling supplement.
-Brianne Harrison

Baltimore, MD (May 14)— Students at Johns Hopkins University developed a thin strip that dissolves in the mouth and is capable of delivering rotavirus vaccine to infants. The film dissolves within one minute, prompting the baby to swallow the vaccine. The medication is coated with a material that protects it from stomach acids but allows it to be released in the small intestine. The vaccine will be especially useful in developing countries, where rotavirus currently causes more than 500,000 deaths per year. Current vaccines must be chilled for transport and storage, making delivery to impoverished areas difficult and expensive. The strips are easy to transport and do not require refrigeration.

Foster City, CA (May 10)Gilead Sciences, Inc. promoted Paul Carter to senior vice-president of international commercial operations. Carter joined the company in 2006 as leader of Gilead's European commercial organization. He previously held various positions at GlaxoSmithKline.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here